ATE477275T1 - Antikörper gegen cd28 - Google Patents
Antikörper gegen cd28Info
- Publication number
- ATE477275T1 ATE477275T1 AT01995797T AT01995797T ATE477275T1 AT E477275 T1 ATE477275 T1 AT E477275T1 AT 01995797 T AT01995797 T AT 01995797T AT 01995797 T AT01995797 T AT 01995797T AT E477275 T1 ATE477275 T1 AT E477275T1
- Authority
- AT
- Austria
- Prior art keywords
- antibodies against
- antibody
- receptor
- interaction
- blocks
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0017025 | 2000-12-26 | ||
| PCT/FR2001/004203 WO2002051871A2 (fr) | 2000-12-26 | 2001-12-26 | Anticorps anti-cd28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE477275T1 true ATE477275T1 (de) | 2010-08-15 |
Family
ID=8858197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01995797T ATE477275T1 (de) | 2000-12-26 | 2001-12-26 | Antikörper gegen cd28 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7723482B2 (de) |
| EP (1) | EP1345969B1 (de) |
| JP (1) | JP4066166B2 (de) |
| AT (1) | ATE477275T1 (de) |
| DE (1) | DE60142794D1 (de) |
| DK (1) | DK1345969T3 (de) |
| ES (1) | ES2353273T3 (de) |
| PT (1) | PT1345969E (de) |
| WO (1) | WO2002051871A2 (de) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002066059A2 (en) * | 2001-02-16 | 2002-08-29 | Genetics Institute, Llc | Agents that specifically block cd28-mediated signaling and uses therefor |
| US20080095774A1 (en) * | 2001-02-16 | 2008-04-24 | Wyeth | Agents and Methods for Specifically Blocking CD28-Mediated Signaling |
| CA2537263C (en) * | 2002-11-27 | 2017-05-30 | Minerva Biotechnologies Corporation | Techniques and compositions for the diagnosis and treatment of cancer (muc1) |
| DK2363410T3 (en) * | 2003-08-26 | 2018-01-15 | Minerva Biotechnologies Corp | ISOFORMER OF MUC1 |
| AU2007331672A1 (en) | 2006-12-15 | 2008-06-19 | Ablynx N.V. | Amino acid sequences that modulate the interaction between cells of the immune system |
| PE20110385A1 (es) | 2008-07-18 | 2011-06-22 | Bristol Myers Squibb Co | Anticuerpo de dominio (dab) que se une a cd28 y no reacciona en forma cruzada con ctla4 |
| NO2344540T3 (de) | 2008-10-02 | 2018-04-28 | ||
| EP2210902A1 (de) * | 2009-01-14 | 2010-07-28 | TcL Pharma | Rekombinante monovalente Antikörper |
| US8465980B2 (en) | 2009-01-28 | 2013-06-18 | Industrial Technology Research Institute | Urine and serum biomarkers associated with diabetic nephropathy |
| FR2951176A1 (fr) | 2009-10-09 | 2011-04-15 | Tcl Pharma | Ligands monovalents du recepteur cd28 humain |
| LT2536764T (lt) * | 2010-02-18 | 2018-10-25 | Ose Immunotherapeutics | Anti-cd28 humanizuoti antikūnai |
| EP2361935A1 (de) * | 2010-02-18 | 2011-08-31 | TcL Pharma | Humanisierte Anti-CD28-Antikörper |
| WO2012158818A2 (en) | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| EP3091032A1 (de) | 2015-05-08 | 2016-11-09 | Miltenyi Biotec GmbH | Cd3-spezifischer, humanisierter antikörper oder fragment davon |
| IL300122A (en) | 2015-11-18 | 2023-03-01 | Merck Sharp ַ& Dohme Llc | Substances that bind to PD1 and/or LAG3 |
| AU2016355569B2 (en) | 2015-11-18 | 2020-01-02 | Merck Sharp & Dohme Llc | CTLA4 binders |
| CA3003777A1 (en) | 2015-11-18 | 2017-05-26 | Merck Sharp & Dohme Corp. | Pd1/ctla4 binders |
| EP3430058A4 (de) | 2016-03-15 | 2019-10-23 | Generon (Shanghai) Corporation Ltd. | Multispezifische fab-fusionsproteine und verwendungen davon |
| WO2018106945A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018183929A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| AU2019234183B2 (en) * | 2018-03-15 | 2025-12-18 | Biond Biologics Ltd. | Methods and compositions for decreasing soluble immune receptor CD28 |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| IL279354B1 (en) | 2018-06-21 | 2026-02-01 | Regeneron Pharma | Bispecific antibodies against psma and against cd28 and their uses |
| EP3843788A1 (de) | 2018-08-30 | 2021-07-07 | HCW Biologics, Inc. | Einkettige chimäre polypeptide und deren verwendungen |
| CN120365435A (zh) | 2018-08-30 | 2025-07-25 | 免疫生物公司 | 单链嵌合多肽和多链嵌合多肽以及其用途 |
| CN112996805A (zh) | 2018-08-30 | 2021-06-18 | Hcw生物科技公司 | 多链嵌合多肽和其用途 |
| EP3847196A4 (de) | 2018-09-07 | 2023-01-04 | ITabMed (HK) Limited | Bispezifische antigenbindende proteine und verwendungen davon |
| EP3860653A1 (de) | 2018-10-05 | 2021-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Verfahren und systeme zur steuerung der agonistischen eigenschaften von variablen antikörperdomänen durch licht |
| EP3883635A1 (de) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Verfahren und vorrichtungen zur behandlung einer krankheit mit biotherapeutika |
| WO2020132810A1 (en) | 2018-12-24 | 2020-07-02 | Generon (Shanghai) Corporation Ltd. | Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof |
| EP3938397A1 (de) | 2019-03-14 | 2022-01-19 | Biond Biologics Ltd. | Mittel zur blockierung von kleinen freisetzungen |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| JP7713393B2 (ja) | 2019-06-21 | 2025-07-25 | イミュニティーバイオ インコーポレイテッド | 多鎖キメラポリペプチドおよびその使用 |
| JP2023509803A (ja) | 2019-12-02 | 2023-03-09 | ビオンド バイオロジクス リミテッド | Ｍｍｐ抑制の使用 |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| EP4103599A1 (de) | 2020-02-11 | 2022-12-21 | HCW Biologics, Inc. | Verfahren zum aktivieren regulatorischer t-zellen |
| KR20220140535A (ko) | 2020-02-11 | 2022-10-18 | 에이치씨더블유 바이올로직스, 인크. | 크로마토그래피 수지 및 이의 용도 |
| US12115191B2 (en) | 2020-02-11 | 2024-10-15 | Immunitybio, Inc. | Methods of treating age-related and inflammatory diseases |
| CN115515982A (zh) | 2020-03-12 | 2022-12-23 | 比昂生物制剂公司 | 具有增加的稳定性的脱落阻断剂 |
| EP4143231A1 (de) | 2020-04-29 | 2023-03-08 | HCW Biologics, Inc. | Anti-cd26-proteine und verwendungen davon |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| EP4157460A1 (de) | 2020-06-01 | 2023-04-05 | HCW Biologics, Inc. | Verfahren zur behandlung von altersbedingten erkrankungen |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| CA3192204A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| EP4313109A1 (de) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Apotransmission-polypeptide und deren verwendung bei der behandlung von krebs |
| EP4320156A1 (de) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Gerüst für bifunctioanlmoleküle mit pd-1- oder cd28- und sirp-bindenden domänen |
| AU2022303363A1 (en) | 2021-06-29 | 2024-01-18 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| US12365743B2 (en) | 2022-02-23 | 2025-07-22 | Xencor, Inc. | Anti-CD28 x anti-PSMA antibodies |
| WO2023168363A1 (en) | 2022-03-02 | 2023-09-07 | HCW Biologics, Inc. | Method of treating pancreatic cancer |
| EP4507711A1 (de) | 2022-04-13 | 2025-02-19 | ImmunityBio, Inc. | Mehrkettiges chimäres polypeptid zur verwendung bei der behandlung von neuroinflammatorischen erkrankungen |
| US20250249278A1 (en) | 2022-04-14 | 2025-08-07 | Institut National de la Santé et de la Recherche Médicale | Methods for controlling the tumor cell killing by light |
| US12600801B2 (en) | 2022-07-11 | 2026-04-14 | Fred Hutchinson Cancer Center | Single-domain antibodies that bind ROR1 |
| US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
| US20240228620A1 (en) | 2022-10-06 | 2024-07-11 | Bicara Therapeutics Inc. | Multispecific proteins and related methods |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| WO2026043906A1 (en) | 2024-08-19 | 2026-02-26 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| US20260049118A1 (en) | 2024-08-19 | 2026-02-19 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| ZA91463B (en) | 1990-01-25 | 1992-09-30 | Bristol Myers Squibb Co | Method of activating cytolytic activity of lymphocytes using anti-cd28 antibody |
| AU7107794A (en) * | 1993-06-10 | 1995-01-03 | Regents Of The University Of Michigan, The | Cd28 pathway immunosuppression |
| US5948893A (en) * | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
-
2001
- 2001-12-26 DK DK01995797.6T patent/DK1345969T3/da active
- 2001-12-26 ES ES01995797T patent/ES2353273T3/es not_active Expired - Lifetime
- 2001-12-26 EP EP01995797A patent/EP1345969B1/de not_active Expired - Lifetime
- 2001-12-26 WO PCT/FR2001/004203 patent/WO2002051871A2/fr not_active Ceased
- 2001-12-26 DE DE60142794T patent/DE60142794D1/de not_active Expired - Lifetime
- 2001-12-26 US US10/450,832 patent/US7723482B2/en not_active Expired - Lifetime
- 2001-12-26 AT AT01995797T patent/ATE477275T1/de active
- 2001-12-26 PT PT01995797T patent/PT1345969E/pt unknown
- 2001-12-26 JP JP2002552964A patent/JP4066166B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004516034A (ja) | 2004-06-03 |
| DE60142794D1 (de) | 2010-09-23 |
| PT1345969E (pt) | 2010-11-17 |
| ES2353273T3 (es) | 2011-02-28 |
| US7723482B2 (en) | 2010-05-25 |
| DK1345969T3 (da) | 2010-11-29 |
| WO2002051871A2 (fr) | 2002-07-04 |
| WO2002051871A3 (fr) | 2002-08-15 |
| EP1345969B1 (de) | 2010-08-11 |
| US20080038273A1 (en) | 2008-02-14 |
| EP1345969A2 (de) | 2003-09-24 |
| JP4066166B2 (ja) | 2008-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60142794D1 (de) | Antikörper gegen cd28 | |
| DE69929235D1 (de) | Spiro-indole als y5-rezeptor antagonisten | |
| ATE265532T1 (de) | Monoklonaler antikörper br110 und dessen anwendung | |
| CY1112458T1 (el) | Ενα αντισωμα ειδικο για διαλυτο baff για χρηση στην αντιμετωπιση του καρκινου | |
| CY1120070T1 (el) | Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους | |
| IL195338A0 (en) | Optimized fc variants and methods for their generation | |
| GEP20105118B (en) | Anti-vegf antibodies | |
| DK1047781T3 (da) | IL-18-receptorer | |
| NO20041325L (no) | Substanser | |
| ES2293973T3 (es) | Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos. | |
| DE69732868D1 (de) | Mittel gegen Juckreiz | |
| MX9603080A (es) | Anticuerpos monoclonales inmuno-estimulantes. | |
| CY1109536T1 (el) | Βελτιωμενες fc πρωτεϊνες συντηξης | |
| ATE225670T1 (de) | Antagonistische anti-avb3 integrin antikörper | |
| MXPA04003291A (es) | Uso de anticuerpos biespecificos para ragular respuestas inmunes. | |
| ATE346869T1 (de) | Agonistische antikörper gegen tie2 | |
| GB2382705A (en) | System and method for on-line service creation | |
| DE60138605D1 (de) | Phenyl-substituierte indole als h3 histaminrezeptorantagonisten | |
| PT1519748E (pt) | Micropartículas com anticorpos monoclonais específicos de cd28 | |
| NO20011162D0 (no) | FremgangsmÕter og preparater for modulering av interaksjonen mellom APJ-reseptoren og HIV-viruset | |
| TR200001313T2 (tr) | Protein etkileşimlerini ve fonksiyonel ilişkileri kaydeden tarama sistemleri | |
| ES2193102T3 (es) | Compuestos de imidocromo en sistemas catalizadores para la polimerizacion de olefinas. | |
| ATE286073T1 (de) | Antikörper gegen spaltprodukte von vimentin | |
| DE69738512D1 (de) | Epstein-barr virus type b ctl epitopen | |
| ATE285789T1 (de) | Mukosale zytotoxische t-lymphozytenantwort |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1345969 Country of ref document: EP |